Abstract: Described herein is an adhesive composite composition. The composition comprises: a plurality of polymeric microspheres dispersed within a (meth)acrylate-based matrix, wherein the polymeric microspheres are derived from 20 to 99 wt % of a (meth)acrylate monomer having a Tg above room temperature and at least 1 wt % of a polar (meth)acrylate monomer; and the (meth)acrylate-based matrix is derived from a C1 to C20 (meth)acrylate ester monomer and at least 1 wt % of a (meth)acrylate macromer. In some embodiments, these composite adhesives show good impact resistance and good shear. In one embodiment, an ionic liquid is added to the adhesive composite composition to aid in electro-debonding of articles.

Abstract: There is provided a modular clothing system comprising a plurality of clothing parts, wherein the plurality of clothing parts includes: a plurality of front clothing parts and a plurality of rear clothing parts; or a front clothing part and a plurality of rear clothing parts; or a plurality of front clothing parts and a rear clothing part, wherein the or each front clothing part is shaped to cover in use at least part of a front part of a body of a wearer, and wherein the or each rear clothing part is shaped to cover in use at least part of a rear part of a body of a wearer, wherein each of the plurality of clothing parts includes at least one fastener element, the or each fastener element of the or each front clothing part linkable to the or each fastener element of the or each rear clothing part, the fastener elements operable to assemble different modular clothings through different combinations of the front and rear clothing parts, the fastener elements operable to disassemble an assembled modular clothin

Abstract: Described herein is a release coating comprising a blend of: (a) a first polymer, wherein the first polymer is a silicone-containing (meth)acrylic polymer; and (b) a second polymer, wherein the second polymer comprises the polymerization reaction product of: (i) a first monomer having an alkyl group with 12 to 24 carbon atoms, a linking group containing a nitrogen or ester group, and a free-radically polymerizable (meth)acryl group; and (ii) a second free-radically polymerizable monomer having less than 12 carbon atoms. Such release coatings can be coated onto a substrate and used as a release coating for pressure sensitive adhesives.

Abstract: A release composition comprising a waterborne latex polymer particles comprising the polymerization reaction product of: i) a first monomer having an alkyl group with 12 to 24 carbon atoms, a nitrogen-containing or ester linking group, and a free-radically polymerizable (meth)acryl group; ii) a second free-radically polymerizable monomer having less than 12 carbon atoms; and iii) a free-radically polymerizable surfactant; and an aqueous carrier liquid. Also described is a method of making a release coated article and articles.

Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.

Abstract: A color shifting heat transfer label includes a carrier and a color design layer on the carrier. The color design layer is formulated from an ink having a color shifting effect. The color design layer is configured to separate from the carrier to define a color shifting feature that is adhered to a target object upon application of heat and pressure. The color shifting feature is adhered to the target object to define a plane defined by the color shifting feature such that the color shifting feature exhibits a first color when viewed from an angle of about 90 degrees relative to the plane defined by the color shifting feature and a second color, different from the first color when viewed from an angle of about 45 degrees or less relative to the plane defined by the color shifting feature.

Abstract: A color shifting heat transfer label includes a carrier and a color design layer on the carrier. The color design layer is formulated from an ink having a color shifting effect. The color design layer is configured to separate from the carrier to define a color shifting feature that is adhered to a target object upon application of heat and pressure. The color shifting feature is adhered to the target object to define a plane defined by the color shifting feature such that the color shifting feature exhibits a first color when viewed from an angle of about 90 degrees relative to the plane defined by the color shifting feature and a second color, different from the first color when viewed from an angle of about 45 degrees or less relative to the plane defined by the color shifting feature.

Abstract: Aspects of the present disclosure include a complete genomic analysis device and methods of use thereof for high throughput genomic analysis of biological samples.

Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.

Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.

Abstract: Aspects of the present disclosure include a complete genomic analysis device and methods of use thereof for high throughput genomic analysis of biological samples.

Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.

Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.

Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.

Abstract: Aspects of the present disclosure provide a composite liquid cell handling system, composite liquid cell processing methods, and dispensing heads for use in the systems and methods.

Abstract: The invention relates to a method for detecting a foreign cell in a tissue of the upper intestinal tract, sold method comprising: (a) providing a sample of cells from the epithelium layer of the tissue of interest; (b) preparing the cells into a cohesive cluster; (c) staining cells from the cohesive cluster using haematoxylin and eosin (H&E) stain; (d) observing the stained cells; and (e) inferring the presence or absence of foreign cell(s) from the observations of Id), The invention also relates to a method for aiding the diagnosis of an inflammatory condition of the upper intestinal tract in a subject, said method comprising detecting a foreign cell as described above, wherein detection of foreign cell(s) in step (e) infers that the subject has an inflammatory condition of the upper intestinal tract.

Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.

Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.

Abstract: The invention relates to the development of chimeric OpsA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.